JPMorgan added chemical and specialty materials maker Celanese to its focus list, maintaining its overweight rating and raising its price target to $76 from $68, implying 76% upside. Analyst Jeffery Zekauskas called the stock « unloved » and expects a meaningful lift in Acetyl Chain segment earnings in 2026 due to price inflation in acetic acid derivatives such as VAM and VAE. The shares have lost around 10% year-to-date in 2026 despite better-than-expected Q2 results, with investors concerned about the company’s leverage and high net debt-to-EBITDA ratio. Of the 18 analysts covering the stock, 10 recommend a buy or strong buy.
Source: Read the original article
